Additional Oncogenic Alterations in RAS -Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Authors:
- Athanasios BikasABAthanasios Bikas
- Sara AhmadiSASara Ahmadi
- Theodora PappaTPTheodora Pappa
- Ellen MarquseeEMEllen Marqusee
- Kristine WongKWKristine Wong
- Matthew A. NehsMNMatthew A. Nehs
- Nancy L. ChoNCNancy L. Cho
- Jacob HaaseJHJacob Haase
- Gerard M. DohertyGDGerard M. Doherty
- Kartik SehgalKSKartik Sehgal
- Justine A. BarlettaJBJustine A. Barletta
- Erik K. AlexanderEAErik K. Alexander
- 16 May 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (14) , 2678-2685
Abstract
Purpose: RAS mutations occur across the spectrum of thyroid neoplasms, and more tools are needed for better prognostication. The objective of this study was to evaluate how additional genetic events affecting key genes modify prognosis in patients with RAS-mutant thyroid cancers, and specifically differentiated thyroid cancers (DTC). Experimental Design: We performed a clinical–genomic analysis of consecutive patients with DTC, poorly differentiated (PDTC), or anaplastic thyroid cancer (ATC) between January 2014 and December 2021, in whom a custom-targeted next-generation sequencing assay was performed. Patients harboring RAS mutations were included, and we compared their clinical features and outcomes based upon the presence of additional oncogenic alterations. Results: Seventy-eight patients were identified, with 22% (17/78) harboring a driver RAS mutation plus an additional oncogenic alteration. All six (100%) ATCs had an additional mutation. Compared with DTCs harboring a solitary RAS mutation, patients with DTC with RAS and additional mutation(s) were more likely to be classified as American Thyroid Association high-risk of recurrence (77% vs. 12%; P < 0.001) and to have larger primary tumors (4.7 vs. 2.5 cm; P = 0.002) and advanced stage (III or IV) at presentation (67% vs. 3%; P < 0.001). Importantly, over an average 65-month follow-up, DTC-specific-mortality was more than 10-fold higher (20% vs. 1.8%; P = 0.011) when additional mutations were identified. Conclusions: Identification of key additional mutations in patients with RAS-mutant thyroid cancers confers a more aggressive phenotype, increases mortality risk in DTC, and can explain the diversity of RAS-mutated thyroid neoplasia. These data support genomic profiling of DTCs to inform prognosis and clinical decision-making.Keywords
All Related Versions
Funding Information
- National Cancer Institute (1K22CA230381)
- Harvard Catalyst (UL1 TR002541)
This publication has 38 references indexed in Scilit:
- Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpressionEndocrine-Related Cancer, 2014
- RAS Mutations in Thyroid CancerThe Oncologist, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- The Associations Between RAS Mutations and Clinical Characteristics in Follicular Thyroid Tumors: New Insights from a Single Center and a Large Patient CohortThyroid®, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011
- The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt PathwayThe Journal of Clinical Endocrinology & Metabolism, 2011
- Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivoCancer Research, 2009
- Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targetsCurrent Opinion in Cell Biology, 2009
- Thyroid carcinoma: molecular pathways and therapeutic targetsLaboratory Investigation, 2008